Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sarepta TherapeuticsMEX:SRPT 36 PB Ratio is 1.14 as of Jul. 14, 2026, which is 88% below its 10-year median of 9.44. GuruFocus rates MEX:SRPT with a GF Score™ of 36/100 and a GF Value™ of MXN2,058.94 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,228 Biotechnology companies, Sarepta Therapeutics ranks better than 75.41% on this metric.
The historical rank and industry rank for Sarepta Therapeutics's PB Ratio or its related term are showing as below:
MEX:SRPT'
s PB Ratio Range Over the Past 10 Years
Min: 0.86 Med: 9.44 Max: 35.55
Current: 1.32
During the past 13 years, Sarepta Therapeutics's highest PB Ratio was 35.55. The lowest was 0.86. And the median was 9.44.
MEX:SRPT's PB Ratio is ranked better than 75.41% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs MEX:SRPT: 1.32
During the past 12 months, Sarepta Therapeutics's average Book Value Per Share Growth Rate was 22.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 35.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 4.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sarepta Therapeutics was 63.50% per year. The lowest was -44.00% per year. And the median was 2.30% per year.
Back to Basics: PB Ratio
Sarepta Therapeutics (MEX:SRPT) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sarepta Therapeutics PB Ratio Related Terms
Sarepta Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sarepta Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sarepta Therapeutics (MEX:SRPT) has a PB Ratio of 1.14 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sarepta Therapeutics and its competitors. This is 88% below median its historical median of 9.44. Over the past decade, Sarepta Therapeutics' PB Ratio has ranged from 0.86 to 35.55. According to the industry distribution chart, Sarepta Therapeutics ranks #302 out of 1228 companies in the Biotechnology industry, placing it in the top 24.6%.
Is Sarepta Therapeutics' PB Ratio too high?
Sarepta Therapeutics' current PB Ratio of 1.14 is 88% below median its 10-year median of 9.44. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 35.55. The Biotechnology industry median PB Ratio is 2.89. Sarepta Therapeutics' value of 1.14 is 60.5% below this industry median. Based on the distribution chart, Sarepta Therapeutics ranks #302 out of 1228 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sarepta Therapeutics has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' PB Ratio compare to ZYME and BCAX?
According to the Biotechnology industry distribution chart, Sarepta Therapeutics ranks #302 out of 1228 companies for PB Ratio. This places Sarepta Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.89. Sarepta Therapeutics' value of 1.14 is 60.5% below this benchmark. Historically, Sarepta Therapeutics' own PB Ratio has ranged from 0.86 to 35.55 over the past decade. While the company's 10-year median is 9.44 vs. the industry median of 2.89, Sarepta Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sarepta Therapeutics's current PB Ratio of 1.14 is 60.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sarepta Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sarepta Therapeutics's current PB Ratio is 1.14, which is 88% below median its own 10-year median of 9.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,058.94, compared to a current price of MXN294.00 — trading 85.7% below its estimated fair value. The current PB Ratio is 1.14, which is 88% below median its 10-year median of 9.44 and 60.5% below the Biotechnology industry median of 2.89. Sarepta Therapeutics' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current PB Ratio is 1.14 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of MXN294.00 is trading 85.7% below its estimated GF Value™ of MXN2,058.94.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for MEX:SRPT:
PB Ratio: 1.14 (88% below median its 10-year median of 9.44)
GF Value™: MXN2,058.94 vs. price of MXN294.00 (85.7% below fair value)
Industry Position: 60.5% below the Biotechnology median (#302 of 1228)
No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
36GF Score
Get the complete analysis for MEX:SRPT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SRPT has been successfully added to your 
